Investors

Investors

Company Profile

Arena is a biopharmaceutical company focused on discovering and developing novel, small molecule drugs. We are currently directing our activities and resources primarily on:

 

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events & Presentations
Corporate Presentation
More information is coming soon.
Annual Report and Proxy Statement
Date Title and Summary
Toggle Summary Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial
- Olorinab investigated in three doses, 10 mg, 25 mg, and 50 mg, for abdominal pain associated with IBS-C & IBS-D - Trial did not meet primary endpoint in broad study population - Moderate to severe pain population at 50 mg showed statistically significant, clinically meaningful improvement vs
Toggle Summary Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter
- Significant pipeline progress with potentially first- or best-in-class drug candidates - Strong cash position of $1.1 billion as of December 31, 2020 SAN DIEGO --(BUSINESS WIRE)--Feb. 23, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial